NSCLC 1st Line

For advanced non-squamous* NSCLC, build survival with ALIMTA/cisplatin as 1st line treatment

ALIMTA/cisplatin is the first line choice that can benefit a wide range of nonsquamous* NSCLC patients.1-3

Alimta/Cisplatin – First platinum doublet to exceed survival plateau in NSCLC1

  • Superior survival in non-squamous NSCLC1-3
  • 12.6-month median survival in patients with adenocarcinoma1-3
  • Favorable safety profile1

A prespecified analysis of the impact of NSCLC histology on overall survival was conducted. Clinically relevant differences in survival according to histology were observed.1-3

ALIMTA in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.3

View trial design for first line treatment of advanced NSCLC of nonsquamous* cell histology.

*Adenocarcinoma, large cell carcinoma, and other histologies.


  1. Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
  2. Scagliotti G, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14:253-263.
  3. Alimta Prescribing Information (EUSPC12NOV2012)

Largest 1st line advanced NSCLC trial: 1725 patients*1

ALIMTA/cisplatin vs GEMZAR/cisplatin

Phase III, open-label, randomised trial to compare overall survival against a proven first line treatment in a well-balanced patient population1

View patient breakdown by histology or efficacy by histology for first line treatment of advanced NSCLC of nonsquamous cell histology.

Trail Design1

Patient breakdown by histology(test)

In the JMDB study, nonsquamous NSCLC was the predominant histology.1

Trail Design2

About GEMZAR

GEMZAR (gemcitabine), in combination with cisplatin, is indicated as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer. See the GEMZAR Prescribing Information.

*Largest multicentre, randomised, phase III trial.
Adenocarcinoma, large cell carcinoma, and other histologies.


  1. Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
  2. Alimta Prescribing Information (EUSPC12NOV2012)

Superior survival for 1st line advanced NSCLC patients with nonsquamous* histology

Prespecified analysis confirms histology-based survival with ALIMTA in nonsquamous* NSCLC1-3.

Adenocarcinoma median overall survival1-3
ALIMTA/cisplatin 12.6 months
GEMZAR/cisplatin 10.9 months

Adenocarcinoma one-year survival rates4

  • ALIMTA/cisplatin 51 %
  • GEMZAR/cisplatin 45 %

Scroll to view first line trial information for NSCLC patients with large cell carcinoma or squamous cell carcinoma, as well as survival for overall population.

Click here to view tolerability for first line treatment of advanced NSCLC with ALIMTA/cisplatin.

Efficacy histology1

Nonsquamous* patients: large cell carcinoma

    Median overall survival1-3
  • ALIMTA/cisplatin 10.4 months
  • GEMZAR/cisplatin 6.7 months
    One-year survival rates4
  • ALIMTA/cisplatin 42 %
  • GEMZAR/cisplatin 28 %
Efficacy histology3

Squamous cell carcinoma patients

    Median overall survival1-3
  • GEMZAR/cisplatin 10.8 months
  • ALIMTA/cisplatin 9.4 months
    One-year survival rates4
  • GEMZAR/cisplatin 44 %
  • ALIMTA/cisplatin 36 %
Efficacy histology5

Survival for overall population

    Median overall survival1,3
  • ALIMTA/cisplatin 10.3 months
  • GEMZAR/cisplatin 10.3 months
    One-year survival rates1
  • ALIMTA/cisplatin 43.5 %
  • GEMZAR/cisplatin 41.9 %
Efficacy histology7

About GEMZAR

GEMZAR (gemcitabine), in combination with cisplatin, is indicated as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer. See the GEMZAR Prescribing Information.

*Adenocarcinoma, large cell carcinoma, and other histologies.
Compared with GEMZAR/cisplatin.


  1. Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
  2. Scagliotti G, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14:253-263.
  3. Alimta Prescribing Information (EUSPC12NOV2012)
  4. Data on file. Lilly Research Laboratories (H3ENOV2007).

Efficacy supported by tolerability advantages for ALIMTA in 1st line advanced NSCLC1,2

Key haematological grades 3/4 drug-related toxicities were significantly lower for ALIMTA/cisplatin compared with GEMZAR/cisplatin.1,2

Scroll to view select grades 3/4 nonhaematological toxicities and transfusion and growth factor support

Click here to view dosing for first line treatment of advanced NSCLC nonsquamous* cell histology.

Alimta TolerabilityF1

Select grades 3/4 nonhaematological toxicities

  • For ALIMTA/cisplatin vs GEMZAR/cisplatin, drug-related grades 3/4 febrile neutropenia and alopecia were significantly lower whereas drug-related grades 3/4 nausea were higher1,2
  • Despite the higher rate of grades 3/4 nausea on the ALIMTA/cisplatin arm, there was no difference between arms in terms of grades 3/4 vomiting or any grade dehydration1,2
Alimta Tolerability

Transfusion and growth factor support

Use of transfusions (RBC and platelet) and haematopoietic growth factors was lower in the ALIMTA/cisplatin arm compared with the GEMZAR/cisplatin arm.1,2

Alimta Tolerability

About GEMZAR

GEMZAR (gemcitabine), in combination with cisplatin, is indicated as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer. See the GEMZAR Prescribing Information.

* Adenocarcinoma, large cell carcinoma, and other histologies.


  1. SScagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
  2. Scagliotti G, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14:253-263.
  3. Alimta Prescribing Information (EUSPC12NOV2012)

ALIMTA has a convenient 3-week dosing schedule1

Dosing convenience for your first line patients, with infusion on Day 1 only1

The recommended dose of ALIMTA is 500 mg/m2 IV on Day 1 of each 21-day cycle in combination with cisplatin 75 mg/m2 IV beginning 30 minutes after ALIMTA administration.1

Alimta 1stline

Dose modifications

Refer to the Alimta Prescribing Information for proper monitoring and dose modifications for ALIMTA in combination with cisplatin.1

Alimta 1stline
  1. Alimta Prescribing Information (EUSPC12NOV2012)


Last Update: 19 Oct 15

Top
TGlsbHkwMS0wNjIwMTY=